Shionogi: Pipeline Products Performance Potential

A Detailed and Comprehensive Overview of Current Financial Position, Company Strategy, Product and Pipeline Analysis.

Therapeutic Area Focus

Key Product Analysis and Forecasting

Infectious Diseases

• Avelox (Moxifloxacin)
• Finibax (Doripenem)
• Flomox (Cefcapene Pivoxil)
• Flumarin (Flomoxef Sodium)
• Tamiflu (Oseltamivir)
• Vancomycin (Vancomycin Hydrochloride)

Metabolic Syndrome

Crestor (Rosuvastatin Calcium)

Anticancer

Imunace (Recombinant Interleukin-2)

Neurology

Oxycontin (Oxycodone)

Allergy

Claritin (Loratadine)

Circulatory System

Dobutrex (Dobutamine)

Operational Data

• A Wealth of Background and Detail
• A Full 5-Year Financial Performance Assessment
• Key Corporate Events
• Key Agreements
• Infrastructure
• Subsidiaries and Joint Ventures

• Executive Summary
  • Introduction
  • Current Financial Position
  • Company Performance
  • Segment Performance
  • Geographic Performance
  • Company Strategy
  • R&d Strategy
  • Mergers, Acquisitions and Divestitures
  • Key Agreements
  • Production
  • Employees
  • Product Performance Forecasts
  • Pipeline Analysis
  • Conclusions
• Therapeutic Area Focus
  • R&d Pipelin E
  • in Fectio Us Diseases
  • Marketed Products
  • Avelox
  • Finibax
  • Flomox
  • Flumarin
  • Tamiflu
  • Vancomycin
  • Others
  • R&d Projects
  • Peramivir
  • S-013420
  • S-349572
  • Growth Forecast
• Metabolic Syndrome
  • Marketed Products
  • Crestor
  • Others
  • R&d Projects
  • Irbesartan
  • S-0139
  • S-2367
  • S-888711
  • Growth Forecast
• Anticancer
  • Marketed Products
  • Imunace
  • Others
  • R&d Projects
  • Growth Forecast
• Neurology
  • Marketed Products
  • Oxycontin
  • Others
  • R&d Projects
  • Duloxetine (Ly248686)
  • S-0373
  • Growth Forecast
• Allergy
  • Marketed Products
  • Claritin
  • Others
  • R&d Projects
  • Pirfenidone
  • S-555739
  • S-777469
  • Growth Forecast
  • Other
  • Marketed Products
  • Cetrotide
  • Others
  • R&d Projects
  • Adapalene Gel
• Appendix 1 - Financial Performance
  • Full Year Results 2007
• Appendix 2 - Key Corporate Events
• Appendix 3 - Key Agreements
  • Anthera Pharmaceuticals Inc
  • Astrazeneca
  • Bayer
  • Biocryst Pharmaceuticals Inc
  • Bristol-Myers Squibb
  • Eli Lilly
  • Enanta Pharmaceuticals Inc
  • Galderma Kk
  • Glaxosmithkline
  • Johnson & Johnson
  • Marnac Inc/Kdl Inc
  • Morphosys Ag
  • Mundipharma Bv
  • Oncotherapy Science Inc (Ots)
  • Purdue Pharma Lp
  • Roche
  • Sanofi-Aventis
  • Schering-Plough
  • Quark Biotech Inc (Qbi)
• Appendix 4 - Infrastructure
  • Research and Development Facilities
  • Manufacturing Facilities
• Appendix 5 - Major Pharmaceutical Subsidiaries/Joint Ventures
  • Subsidiaries
  • Joint-Venture Companies
• Appendix 6 - Product Index
• Index of Tables
  • Principal Operating Results
  • Capital Expenditure by Business Area
  • Sales by Business Area
  • Operating Income by Business Area
  • Total Assets by Business Area
  • Recent Product Approvals
  • Major Products, Therapeutic Areas and Sales
  • Major Infectious Diseases Products, 2007
  • Major Metabolic Syndrome Products, 2007
  • Major Anticancer Products, 2007
  • Major Neurology Products, 2007
  • Major Allergy Products, 2007
• Index of Charts
  • Sales, Costs and Operating Income
  • R&d Expenditure and Capital Expenditure
  • Sales by Business Area, 2007
  • Operating Income by Business Area, 2007
  • Total Assets by Business Area, 2007
  • Sales of Top 10 Products (2002a-2012e)
  • Sales of Top Ten Products, 2007
  • Avelox Sales (2002a-2012e)
  • Finibax Sales (2002a-2012e)
  • Flomox Sales (2002a-2012e)
  • Flumarin Sales (2002a-2012e)
  • Vancomycin Sales (2002a-2012e)
  • Crestor Sales (2002a-2012e)
  • Irbesartan Sales (2008e-2012e)
  • Imunace Sales (2002a-2012e)
  • Oxycontin Sales (2002a-2012e)
  • Duloxetine Sales (2009e-2013e)
  • Claritin Sales (2002a-2012e)
  • Pirfenidone Sales (2009e-2013e)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&d Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity